Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Insmed Inc ha un obiettivo di prezzo di consenso pari a $126.25, stabilito in base alle ultime valutazioni degli analisti di 23. Le ultime 3 valutazioni degli analisti sono state rilasciate da Morgan Stanley, JP Morgan y Truist Securities il agosto 21, 2025, agosto 20, 2025 y agosto 14, 2025. Con un obiettivo di prezzo medio di $139.33 tra le Morgan Stanley, JP Morgan y Truist Securities, c'è un implicito 5.39% upside per Insmed Inc da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
Morgan Stanley
JP Morgan
Truist Securities
Stifel
Morgan Stanley
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Insmed
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
08/21/2025 | 8.92% | Morgan Stanley | $126 → $144 | Maintains | Equal-Weight | |||
08/20/2025 | 2.11% | JP Morgan | $111 → $135 | Maintains | Overweight | |||
08/20/2025 | — | William Blair | — | Initiates | → Outperform | |||
08/14/2025 | 5.14% | Truist Securities | $126 → $139 | Maintains | Buy | |||
08/14/2025 | 9.67% | Stifel | $121 → $145 | Maintains | Buy | |||
08/13/2025 | -4.7% | Morgan Stanley | $112 → $126 | Downgrade | Overweight → Equal-Weight | |||
08/13/2025 | 81.53% | HC Wainwright & Co. | $120 → $240 | Maintains | Buy | |||
08/13/2025 | 5.89% | UBS | $133 → $140 | Maintains | Buy | |||
08/13/2025 | 4.38% | RBC Capital | $120 → $138 | Maintains | Outperform | |||
08/13/2025 | 7.4% | Goldman Sachs | $114 → $142 | Maintains | Buy | |||
08/13/2025 | 24.8% | Mizuho | $130 → $165 | Maintains | Outperform | |||
08/13/2025 | 11.94% | Jefferies | $129 → $148 | Maintains | Buy | |||
08/12/2025 | 5.89% | Wells Fargo | $130 → $140 | Maintains | Overweight | |||
08/08/2025 | -9.24% | RBC Capital | $108 → $120 | Maintains | Outperform | |||
08/08/2025 | 0.6% | UBS | $124 → $133 | Maintains | Buy | |||
07/22/2025 | -1.67% | Wells Fargo | $119 → $130 | Maintains | Overweight | |||
07/17/2025 | -18.31% | Morgan Stanley | $102 → $108 | Maintains | Overweight | |||
07/08/2025 | -16.04% | JP Morgan | $90 → $111 | Maintains | Overweight | |||
06/11/2025 | -15.29% | Goldman Sachs | $100 → $112 | Maintains | Buy | |||
06/11/2025 | -16.8% | Mizuho | $96 → $110 | Maintains | Outperform | |||
06/11/2025 | -19.82% | RBC Capital | $99 → $106 | Maintains | Outperform | |||
06/11/2025 | -22.85% | Morgan Stanley | $90 → $102 | Maintains | Overweight | |||
06/11/2025 | -17.56% | B of A Securities | $94 → $109 | Maintains | Buy | |||
06/11/2025 | -9.99% | Wells Fargo | $107 → $119 | Maintains | Overweight | |||
06/11/2025 | -9.24% | HC Wainwright & Co. | $90 → $120 | Maintains | Buy | |||
06/10/2025 | -13.02% | Leerink Partners | $100 → $115 | Maintains | Outperform | |||
05/13/2025 | -20.58% | Jefferies | → $105 | Initiates | → Buy | |||
05/09/2025 | -17.56% | UBS | $110 → $109 | Maintains | Buy | |||
04/22/2025 | -31.93% | HC Wainwright & Co. | $90 → $90 | Reiterates | Buy → Buy | |||
03/20/2025 | -27.39% | B of A Securities | $92 → $96 | Maintains | Buy | |||
03/19/2025 | -24.36% | RBC Capital | $100 → $100 | Reiterates | Outperform → Outperform | |||
03/06/2025 | -16.8% | UBS | $105 → $110 | Maintains | Buy | |||
02/25/2025 | -24.36% | RBC Capital | → $100 | Initiates | → Outperform | |||
02/25/2025 | -23.61% | Guggenheim | $101 → $101 | Reiterates | Buy → Buy | |||
02/24/2025 | -31.93% | HC Wainwright & Co. | $90 → $90 | Reiterates | Buy → Buy | |||
02/21/2025 | -18.31% | Truist Securities | $105 → $108 | Maintains | Buy | |||
02/21/2025 | -27.39% | Stifel | $97 → $96 | Maintains | Buy | |||
02/21/2025 | -31.93% | HC Wainwright & Co. | $90 → $90 | Reiterates | Buy → Buy | |||
02/20/2025 | — | Cantor Fitzgerald | — | Reiterates | Overweight → Overweight | |||
02/19/2025 | — | Cantor Fitzgerald | — | Reiterates | Overweight → Overweight | |||
02/19/2025 | -19.07% | Wells Fargo | $85 → $107 | Maintains | Overweight | |||
02/18/2025 | -27.39% | Mizuho | $88 → $96 | Maintains | Outperform | |||
02/11/2025 | -26.63% | Stifel | $88 → $97 | Maintains | Buy | |||
02/07/2025 | -30.41% | JP Morgan | $83 → $92 | Maintains | Overweight | |||
02/07/2025 | -23.61% | Guggenheim | $95 → $101 | Maintains | Buy | |||
02/06/2025 | -31.93% | Morgan Stanley | $85 → $90 | Maintains | Overweight | |||
11/22/2024 | -37.22% | JP Morgan | $74 → $83 | Maintains | Overweight | |||
11/14/2024 | -33.44% | Mizuho | $92 → $88 | Maintains | Outperform | |||
11/01/2024 | -20.58% | Truist Securities | $100 → $105 | Reiterates | Buy → Buy | |||
11/01/2024 | -31.93% | HC Wainwright & Co. | $90 → $90 | Reiterates | Buy → Buy | |||
10/11/2024 | -24.36% | Truist Securities | $85 → $100 | Maintains | Buy | |||
10/09/2024 | -34.95% | B of A Securities | $84 → $86 | Maintains | Buy | |||
10/03/2024 | -44.03% | JP Morgan | $72 → $74 | Maintains | Overweight | |||
09/09/2024 | — | Cantor Fitzgerald | — | Reiterates | → Overweight | |||
08/29/2024 | -31.93% | HC Wainwright & Co. | $90 → $90 | Reiterates | Buy → Buy | |||
08/15/2024 | -30.41% | Mizuho | $82 → $92 | Maintains | Outperform | |||
08/12/2024 | -35.71% | Truist Securities | $88 → $85 | Maintains | Buy | |||
08/12/2024 | -31.93% | HC Wainwright & Co. | $90 → $90 | Reiterates | Buy → Buy | |||
08/09/2024 | -35.71% | Wells Fargo | $77 → $85 | Maintains | Overweight | |||
08/09/2024 | -25.88% | TD Cowen | $75 → $98 | Maintains | Buy | |||
08/09/2024 | -36.46% | UBS | $78 → $84 | Maintains | Buy | |||
08/09/2024 | -33.44% | Stifel | $74 → $88 | Maintains | Buy | |||
07/12/2024 | -35.71% | Morgan Stanley | $60 → $85 | Maintains | Overweight | |||
07/10/2024 | -22.85% | Goldman Sachs | $74 → $102 | Maintains | Buy | |||
07/09/2024 | -28.14% | Guggenheim | $70 → $95 | Maintains | Buy | |||
07/08/2024 | -31.93% | HC Wainwright & Co. | $70 → $90 | Maintains | Buy | |||
07/05/2024 | -37.22% | B of A Securities | $83 → $83 | Maintains | Buy | |||
07/02/2024 | -47.05% | HC Wainwright & Co. | $70 → $70 | Reiterates | Buy → Buy | |||
07/01/2024 | -33.44% | Truist Securities | $68 → $88 | Maintains | Buy | |||
06/28/2024 | -37.22% | B of A Securities | $62 → $83 | Maintains | Buy | |||
06/21/2024 | -43.27% | Evercore ISI Group | $42 → $75 | Maintains | Outperform | |||
06/20/2024 | — | Cantor Fitzgerald | — | Reiterates | → Overweight | |||
06/20/2024 | -45.54% | JP Morgan | $55 → $72 | Maintains | Overweight | |||
06/07/2024 | -37.98% | Mizuho | $36 → $82 | Maintains | Buy | |||
06/05/2024 | -44.03% | Stifel | $67 → $74 | Maintains | Buy | |||
05/31/2024 | -49.32% | Stifel | $39 → $67 | Maintains | Buy | |||
05/29/2024 | -49.32% | TD Cowen | $45 → $67 | Maintains | Buy | |||
05/29/2024 | -56.13% | UBS | $46 → $58 | Maintains | Buy | |||
05/29/2024 | -44.03% | Goldman Sachs | $49 → $74 | Maintains | Buy | |||
05/29/2024 | -41.76% | Wells Fargo | $55 → $77 | Maintains | Overweight | |||
05/29/2024 | -48.57% | Truist Securities | $48 → $68 | Maintains | Buy | |||
05/29/2024 | -52.35% | Barclays | $40 → $63 | Maintains | Overweight | |||
05/29/2024 | -58.4% | JP Morgan | $36 → $55 | Maintains | Overweight | |||
05/29/2024 | -53.1% | B of A Securities | $40 → $62 | Maintains | Buy | |||
05/29/2024 | -47.05% | HC Wainwright & Co. | $52 → $70 | Maintains | Buy | |||
05/28/2024 | -54.62% | Morgan Stanley | $43 → $60 | Maintains | Overweight | |||
05/28/2024 | -69.75% | B of A Securities | $40 → $40 | Maintains | Buy | |||
05/16/2024 | -63.69% | Truist Securities | $48 → $48 | Maintains | Buy | |||
05/15/2024 | -62.94% | Goldman Sachs | $40 → $49 | Maintains | Buy | |||
05/14/2024 | -60.67% | HC Wainwright & Co. | $52 → $52 | Reiterates | Buy → Buy | |||
05/13/2024 | -72.77% | Mizuho | $35 → $36 | Maintains | Buy | |||
05/10/2024 | -67.48% | Morgan Stanley | $40 → $43 | Maintains | Overweight | |||
04/23/2024 | -63.69% | Truist Securities | → $48 | Initiates | → Buy | |||
04/11/2024 | -69.75% | Barclays | $37 → $40 | Maintains | Overweight | |||
04/01/2024 | -58.4% | Wells Fargo | $55 → $55 | Maintains | Overweight | |||
02/27/2024 | -59.16% | Guggenheim | $52 → $54 | Maintains | Buy | |||
02/27/2024 | -65.21% | UBS | → $46 | Initiates | → Buy | |||
02/23/2024 | -69.75% | B of A Securities | $37 → $40 | Maintains | Buy | |||
02/15/2024 | -68.23% | Wolfe Research | → $42 | Initiates | → Outperform | |||
11/20/2023 | -72.77% | JP Morgan | → $36 | Reinstates | → Overweight |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Insmed (INSM)?
El último precio objetivo de Insmed (NASDAQ:INSM) fue comunicado por Morgan Stanley el agosto 21, 2025. La firma de analistas fijó un precio objetivo para $144.00 que espera INSM a rise dentro de 12 meses (un posible 8.92% upside). 55 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Insmed (INSM)?
La última calificación de analistas para Insmed (NASDAQ:INSM) fue proporcionada por Morgan Stanley, y Insmed mantuvo su equal-weight calificación.
¿Cuándo se produjo la última revisión al alza de Insmed (INSM)?
No hay última actualización para Insmed
¿Cuándo fue la última revisión a la baja de Insmed (INSM)?
La última revisión a la baja de Insmed Inc se produjo en agosto 13, 2025, cuando Morgan Stanley cambió su precio objetivo de $112 a $126 para Insmed Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Insmed (INSM)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Insmed, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Insmed se registró el agosto 21, 2025, por lo que la próxima calificación estará disponible en torno al agosto 21, 2026.
¿Es correcta la calificación de los analistas sobre Insmed (INSM)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Insmed (INSM) fue un mantuvo con un precio objetivo de $126.00 a $144.00. El precio actual al que cotiza Insmed (INSM) es de $132.21, que es within del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.